Advertisement|Remove ads.

Anupam Rasayan’s stock appears significantly overvalued and technically overbought, signaling caution fundamentally and on the charts.
According to SEBI-registered research analyst Rajneesh Sharma, the specialty chemicals firm, known for its custom synthesis work with global clients, is currently trading at steep valuations.
“Anupam Rasayan is a good company, but at this price, it’s simply too expensive,” he said.
He flagged a price-to-earnings ratio of 134, which is more than four times the sector median of 31.33, and a price-to-book ratio of 4.38, above the industry range of 2–3.
Its Enterprise Value/EBITDA stood at 33.3, compared to a fair range of 12x–20x for chemical companies.
“The market is paying for perfection — and perfection is hard to sustain,” Sharma said.
On return metrics, Sharma noted a return on capital employed (RoCE) of 7.33% and return on equity (RoE) of 3.33%, calling them insufficient for the premium being paid. The dividend yield is just 0.11%.
On the technical charts, Sharma pointed to several cautionary flags: a weekly Relative Strength Index (RSI) of 79.54, historically associated with corrections; proximity to the ₹1,228 resistance zone; and a parabolic rally pattern.
He also said the price action mirrors previous peaks, with the stock pressing against the upper boundary of a long-term rising channel.
Sharma shared a short-term bearish view, a neutral medium-term view, and a bullish long-term outlook.
He advised investors holding the stock to consider booking partial profits near ₹1,200 and to use tight stop-losses.
For new entrants, he recommended waiting for a pullback toward the ₹1,000–₹950 range, and for traders to monitor for rejection near ₹1,228.
The growth story remains valid, but the current price is overextended. Caution is the smart play, Sharma said.
The stock has risen 57.5% so far in 2025.
For updates and corrections, email newsroom[at]stocktwits[dot]com.